Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pacific Edge Limited ( (PFGTF) ) has provided an update.
Pacific Edge Limited reported a decline in Cxbladder test volumes due to the loss of Medicare coverage and the transition of US customers from Detect to Triage. The company is seeking to regain Medicare coverage for its Triage Plus test following the DRIVE Study’s acceptance for publication, which validates its clinical use. Despite a reduction in sales force and ordering clinicians, the company has improved sales force efficiency. The changes have caused market confusion and increased administrative burdens, impacting the number of tests ordered.
More about Pacific Edge Limited
Pacific Edge Limited is a global cancer diagnostics company based in Dunedin, New Zealand. It specializes in the development and commercialization of bladder cancer diagnostic and prognostic tests, particularly the Cxbladder suite, which is used for risk stratification of urothelial cancer. The company operates CLIA certified laboratories in New Zealand and the USA and serves markets in the US, Australasia, Israel, Asia, and South America.
For an in-depth examination of PFGTF stock, go to TipRanks’ Overview page.